Predict your next investment

AliveGen company logo
HEALTHCARE | Drug Discovery
alivegen.com

See what CB Insights has to offer

Founded Year

2014

About AliveGen

AliveGen is a privately held clinical-stage biopharmaceutical company. AliveGen focuses on the discovery and development of novel biotherrapeutics to combat the debiltating muscle and bone loss and the loss of functional capactiy, as occurs in various neuromuscular diseases, cancer cachexia, congestive heart failure, geriatric sarcopenia and frailty, as well as in other chronic diseases.

AliveGen Headquarter Location

810 Lawrence Dr Suite 120

Newbury Park, California, 91320,

United States

(805) 480-9600

Latest AliveGen News

Intervention somewhat effective in reducing serious falls

Jul 8, 2020

Disclosures: Bhasin reports receiving research grant funding unrelated to the research reported in this manuscript from AbbVie, Alivegen, FNIH, FPT, Metro International Biotechnology, NIA, NICHD, NINR, OPKO, and Transition Therapeutics; receiving consultant fees from AbbVie, Aditumbio, and OPKO; and holding equity interest in FPT, LLC. He also reports holding a patent on a method to calculate free testosterone concentration. These conflicts are overseen by and managed according to policies of the Office of Industry Interaction of the Mass General Brigham Health Care System. Please see study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Shalender Bhasin An intervention implemented in primary care settings reduced serious fall injuries among older adults but was not as effective as expected, according to a study published in the New England Journal of Medicine. “Falls are a major public health problem and a leading cause of injury-related deaths among older Americans,” Shalender Bhasin, MD, director of research programs in men’s health, aging and metabolism at Brigham and Women’s Hospital, told Healio Primary Care. “The STRIDE study represents the largest randomized trial of fall injury prevention strategies that has been published to date. The findings have important implications for developing strategies to reduce serious fall injuries in real-world primary care practices.” Reference: Bhasin S, et al. N Engl J Med. 2020;doi:10.1056/NEJMoa2002183. Bhasin and colleagues conducted a pragmatic, cluster-randomized trial to compare enhanced usual care with an intervention to reduce serious fall injuries. In the intervention, participants underwent risk assessment to evaluate risk factors: strength impairment, gait, balance, medication use, postural hypotension and issues with feet or footwear, osteoporosis or vitamin D deficiency, impaired vision and home safety hazards. They were later told the standard protocol-based recommendations to manage these risk factors. Then, individualized care plans that focused on one to three of the identified risk factors were developed for each participant and approved by their primary care physicians. Individualized care plans were implemented by specially trained nurses, and participants subsequently received follow-up care over the phone or during in-person visits to reassess their risk factors and adjust their care plan as needed. The trial included 86 primary care practices across 10 health care systems, with 43 practices assigned to intervention (2,802 participants) and 43 practices (2,649 participants) assigned to enhance usual care. Participants in the study were aged 70 years or older and were determined to be at an increased risk for fall injury due to experiencing two or more falls or a fall-related injury in the previous year or reporting a fear of falling due to issues with balance or walking. Bhasin and colleagues collected data on fall injuries every 4 months through phone interviews with participants. They also assessed EHR records and data from trial sites or CMS claims to identify serious adverse events every 4 months. The researchers hypothesized that the event rate of a serious fall injury — a fracture, dislocated joint or a cut requiring closures after a fall, or a hospitalization for head injury, sprain or strain, bruising, swelling or other serious injury after fall — would decrease by 20% in the intervention group. PAGE BREAK However, Bhasin and colleagues did not observe a significant difference in the rate of first adjudicated serious fall injury between the groups, with 4.9 events per 100 person-years of follow-up in the intervention groups and 5.3 events per 100 person-years of follow-up in the control group (HR = 0.92; 95% CI, 0.8-1.06). In addition, Bhasin and colleagues determined that the rate of first participant-reported fall injury in the intervention group was 25.6 events per 100 person-years of follow-up, and was 28.6 events per 100 person-years of follow up among those who received usual care (HR = 0.90; 95% CI, 0.83-0.99). According to the researchers, both groups had similar rates of hospitalization and death. “The study reflects just how challenging it is to implement interventions to prevent fall injury in the real world,” Bhasin said. “Daily challenges such as being unable to afford transportation or the cost of follow-up care may delay or prevent access for patients to exercise interventions or other medical resources.” In addition, he noted that adherence to assigned exercises may have been “less than optimal” among participants. “We need to think about how to modify our health care systems to enable people to freely access effective interventions, such as exercise, to reduce fall injuries,” Bhasin said.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AliveGen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AliveGen is included in 2 Expert Collections, including Cancer.

C

Cancer

4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

AliveGen Patents

AliveGen has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Inflammations
  • Neurological disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/12/2016

2/9/2021

Olfactory receptors, Rare diseases, Inflammations, Autoimmune diseases, Neurological disorders

Grant

Application Date

4/12/2016

Grant Date

2/9/2021

Title

Related Topics

Olfactory receptors, Rare diseases, Inflammations, Autoimmune diseases, Neurological disorders

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.